SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional ...
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient ...
Q3 2025 Earnings Call Transcript November 12, 2025 Innoviz Technologies Ltd. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. Operator: Ladies and gentlemen, ...
Since that loss, Caleb Williams has continued to build on that step. Last week, he set a career high in On-Target Percentage ...
Record quarterly revenue of $10.1 million in Q3; a more than 6-fold increase YoY and 60% growth QoQ With a pro-forma cash balance of $840.4 million, we believe Ondas has one of the strongest balance ...
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback